Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 7384 (118th)

Creating Hope Reauthorization Act of 2024

referredUnited States· United States Congress· EN

Introduced

15 February 2024

Last action

16 February 2024 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. McCaul, Michael T. [R-TX-10], Rep. Eshoo, Anna G. [D-CA-18], Rep. Bilirakis, Gus M. [R-FL-12], Rep. Barragán, Nanette Diaz [D-CA-44], Rep. Trahan, Lori [D-MA-3], Rep. Burgess, Michael C. [R-TX-26], Rep. Castor, Kathy [D-FL-14], Rep. Kelly, Mike [R-PA-16], Rep. Carter, Earl L. "Buddy" [R-GA-1], Rep. Hudson, Richard [R-NC-8], Rep. Harshbarger, Diana [R-TN-1], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Wilson, Joe [R-SC-2], Rep. Huizenga, Bill [R-MI-4], Rescom. González-Colón, Jenniffer [R-PR-At Large], Mike Garcia, Rep. Davis, Donald G. [D-NC-1], Rep. Ross, Deborah K. [D-NC-2], Rep. Sherrill, Mikie [D-NJ-11], Rep. Balderson, Troy [R-OH-12], Rep. Van Drew, Jefferson [R-NJ-2], Rep. Hern, Kevin [R-OK-1], Rep. Kiley, Kevin [R-CA-3], Rep. Crow, Jason [D-CO-6], Rep. Crenshaw, Dan [R-TX-2], Rep. Duncan, Jeff [R-SC-3], Rep. Joyce, John [R-PA-13], Rep. Lofgren, Zoe [D-CA-18], Rep. Gottheimer, Josh [D-NJ-5], Rep. Weber, Randy K. Sr. [R-TX-14], Rep. Soto, Darren [D-FL-9], Rep. Dunn, Neal P. [R-FL-2], Rep. Harris, Andy [R-MD-1], Rep. Wasserman Schultz, Debbie [D-FL-25], Rep. Davids, Sharice [D-KS-3], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Nickel, Wiley [D-NC-13], Rep. Keating, William R. [D-MA-9], Rep. Wittman, Robert J. [R-VA-1], Rep. Flood, Mike [R-NE-1], Rep. Larson, John B. [D-CT-1], Rep. Houlahan, Chrissy [D-PA-6], Rep. Mullin, Kevin [D-CA-15], Rep. Lawler, Michael [R-NY-17], Rep. DeSaulnier, Mark [D-CA-10], Rep. Bonamici, Suzanne [D-OR-1], Rep. Phillips, Dean [D-MN-3], Rep. Quigley, Mike [D-IL-5]

Subjects

Healthcare

Source updated

27 May 2025

Healthcare

Summary

Creating Hope Reauthorization Act of 2024 This bill extends until FY2029 a Food and Drug Administration program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.)

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 15 February 2024

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 15 February 2024

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 15 February 2024

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 16 February 2024

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 15 February 2024

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 15 February 2024

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 15 February 2024

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 68 sponsors and actors.

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.